Back to news

“Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund

Paul Bravetti (Brenus CEO) about this collaboration : “Despite advances in therapy, a significant number of cancers remain resistant to treatment because the cancer cells can adapt and become invisible to the immune system, causing the patient to relapse. These cold tumors, which escape the immune cells and become for the most part insensitive to immunotherapies (only 5% of colorectal cancers are sensitive, for example), represent one of the greatest challenges for oncology research today. Our STC platform enables the production of new generation immunotherapies that will give the patient’s immune system a step ahead by educating it to anticipate and fight against the resistance and escape mechanisms put in place by cancer cells. The ambition of this technology is to offer a solution to a large population of patients who are currently at an impasse with current treatments. We are delighted with the collaboration with InSphero, which is fully in line with our strategy to develop new drugs for cancer patients.”

Jan Lichtenberg (InShpero CEO) :  “We are delighted to partner with Brenus Pharma on the Allogenix project. 3D cellular approaches will play an important role in the future of innovative therapies such as those delivered by the STC platform, ensuring accelerated and quality data assessment. InSphero’s revolutionary cryopreservation technology will also support complementary developments for the Brenus STC platform. The resulting new medicines will provide solutions for patients suffering from tumors around the world. We look forward to this successful partnership, which would not have been possible without the trust and support of EUROSTARS.”

As a reminder, STC-1010 Drug Product will enter in clinical human development in beg of 2024, After the closing of SERIES A (about 35M€ in May 2023) which will finance this development.

Thanks to the contributors of the project who make it possible ; Benoit Pinteur George Alzeeb lionel Chalus Léa Perles Marinela Lekka Wolfgang Moritz.
Bpifrance Innosuisse
Ulysse Communication.

Jan 2023

About InSphero :
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organon-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.